CORRECTION

Correction to: A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositidedependent Kinase-1

Xin Xia^{1,2†}, Xixi Li^{1,2†}, Fanying Li^{1,2†}, Xujia Wu^{1,2}, Maolei Zhang^{1,2}, Huangkai Zhou^{1,2}, Nunu Huang^{1,2}, Xuesong Yang^{1,2}, Feizhe Xiao³, Dawei Liu⁴, Lixuan Yang^{1,2} and Nu Zhang^{1,2*}

Correction to: Mol Cancer (2019) 18:131 https://doi.org/10.1186/s12943-019-1056-5

In the published article [1], an error was noticed in Fig. 6b. The western blot results were reversed between the overexpression group and the knockdown group of circ-AKT3. The corrected and updated Fig. 6 is provided below. This error does not affect the findings or conclusions of the article.

Author details

¹Department of Neurosurgery, The First Affiliated Hospital of Sun Yat-sen University, No 58, Zhongshan 2 Road, Guangzhou, Guangdong Province 510080, People's Republic of China. ²Guangdong Provincial Key Laboratory of Brain Function and Disease, Precise Medicine Institute, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, People's Republic of China. ³Department of Scientific Research Section, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province 510080, People's Republic of China. ⁴Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong Province 510080, People's Republic of China.

* Correspondence: zhangnu2@mail.sysu.edu.cn

[†]Xin Xia, Xixi Li and Fanying Li contributed equally to this work. ¹Department of Neurosurgery, The First Affiliated Hospital of Sun Yat-sen University, No 58, Zhongshan 2 Road, Guangzhou, Guangdong Province 510080, People's Republic of China

²Guangdong Provincial Key Laboratory of Brain Function and Disease, Precise Medicine Institute, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, People's Republic of China Full list of author information is available at the end of the article



© The Author(s). 2019 **Open Access** This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.









Fig. 6 AKT3-174aa competitively interacts with p-PDK1 form ATK2/3. **a** PDK1 kinase activity was determined in U251 and U373 cells with circ-AKT3 overexpression and their control cells at the indicated time point. Error bars represent three independent experiments, **, p < 0.01. **b** Upper, AKT kinase activity was determined in U251 and U373 cells with circ-AKT3 overexpression and their control cells (48 h); or in SW1783 and Hs683 cells with circ-AKT3 knocking down and their control cells (48 h). Error bars represent three independent experiments, *, p < 0.05, **, p < 0.01. Lower, p-SGK level was determined in indicated cells. **c** U251 cells were transfected with increasingly dose of circ-AKT3. IP was performed by using AKT2, AKT3 and p-PDK1 antibodies. **d** SW1783 cells were transfected with increasingly dose of circ-AKT3 shRNA. IP was performed by using AKT2, AKT3 and p-PDK1 antibodies and followed by immunoblot using indicated antibodies.

Published online: 29 October 2019

Reference

 Xia X, Li X, Li F, Wu X, Zhang M, Zhou H, Huang N, Yang X, Xiao F, Liu D, Yang L, Zhang N. A novel tumor suppressor protein encoded by circular AKT3 RNA inhibits glioblastoma tumorigenicity by competing with active phosphoinositide-dependent Kinase-1. Mol Cancer. 2019;18:131. https://doi. org/10.1186/s12943-019-1056-5.